When a child struggles to sit quietly, finish schoolwork, wait, or manage frustration, what are we observing? Is it a disorder, a developmental skill that has not yet been learned, a response to the environment, or some combination of these? I am interested in how American society answers that question—and what follows when the answer is attention-deficit/hyperactivity disorder, or ADHD.
ADHD is recognized as a neurodevelopmental disorder. It can substantially interfere with daily functioning. At the same time, many behaviors associated with it also occur in ordinary development. A responsible discussion must examine both the possibility of overlooking a genuine disability and the possibility of assigning a disorder to behavior that has another explanation (American Psychiatric Association, n.d.; National Institute of Mental Health [NIMH], n.d.).
American diagnosis rates and worldwide prevalence
The Centers for Disease Control and Prevention (CDC, 2026b) reports that approximately 7 million American children aged 3–17—11.7%—had a current ADHD diagnosis in the 2024 National Survey of Children’s Health. This is a parent-reported estimate of diagnoses, rather than a new diagnostic examination of each child. A 2023 worldwide meta-analysis estimated ADHD prevalence at 7.6% among children aged 3–12 and 5.6% among adolescents aged 12–18 (Salari et al., 2023).
The American figure is higher, but the figures are not directly interchangeable. They involve different ages, years, populations, and assessment methods. Worldwide estimates also include American studies; they are not a clean measure of “everywhere except America.” We cannot use these numbers to conclude that American children have twice as much underlying ADHD or that the difference represents misdiagnosis.
International research has found that diagnostic criteria, information sources, and the requirement to establish impairment explain substantial variation in prevalence estimates. A major review found no evidence of an increase over three decades when methodological differences were accounted for (Polanczyk et al., 2014). That finding concerns the period studied; it cannot settle what has happened since. Higher recorded diagnosis rates may reflect better recognition, different thresholds, access to evaluation, or a mixture of these influences. Lower recorded rates elsewhere may include missed cases.
What the DSM diagnosis actually requires
The DSM-5-TR framework requires a persistent pattern of inattention and/or hyperactivity and impulsivity that interferes with functioning or development. Through age 16, the threshold is at least six symptoms within a symptom group; at age 17 and older, it is at least five. Combined presentation requires the threshold in both groups. Six symptoms divided between the groups do not automatically meet either threshold (CDC, 2026a).
Symptoms must persist for at least six months and be inconsistent with developmental level. Several must have been present before age 12, although diagnosis need not occur before that birthday. Several symptoms must occur in at least two settings. There must be clear interference with, or reduced quality of, social, academic, or occupational functioning. Another mental disorder must not better explain the symptoms, and they must not occur exclusively during a psychotic disorder (CDC, 2026a).
In paraphrased form, the nine inattention symptoms involve recurring difficulty with details, sustained attention, listening, following through, organization, sustained mental effort, keeping necessary belongings, resisting distraction, and remembering daily obligations. The nine hyperactivity and impulsivity symptoms involve fidgeting, leaving one’s seat, inappropriate running or climbing or restlessness, difficulty with quiet leisure, excessive activity, excessive talking, answering prematurely, waiting one’s turn, and interrupting or intruding (American Psychiatric Association, n.d.).
These are patterns assessed in context, not a checklist that converts every energetic or distracted child into a diagnosis. Symptoms cannot be counted simply because a child disagrees, refuses, or does not understand the task. Information from more than one observer helps establish whether the pattern is sufficiently persistent and impairing.
Typical development and behaviors that resemble ADHD
Children gradually learn to wait, organize, persist, and regulate their behavior. Adolescents can show uneven judgment and self-management. The relevant comparison is with children of similar age and developmental level, rather than the most compliant child in a classroom. The following examples illustrate the distinction; they are not diagnostic tests.
| Behavior | Possible developmental variation | Reason for closer assessment |
|---|---|---|
| Activity | A young child needs movement and brief tasks. | Activity repeatedly disrupts functioning beyond age expectations. |
| Attention | Interest and persistence vary with task difficulty or novelty. | Difficulties repeatedly interfere across activities and settings. |
| Organization | A child is learning routines and needs reminders. | Persistent disorganization causes substantial difficulty despite suitable support. |
| Impulsivity | An adolescent sometimes acts before considering consequences. | A recurring pattern substantially impairs relationships, learning, or safety. |
| Frustration | A child becomes upset and is learning how to respond. | The pattern warrants evaluation, but frustration alone does not establish ADHD. |
Relative age is especially relevant. Layton et al. (2018) found higher ADHD diagnosis rates among August-born than September-born children in states with a September 1 kindergarten cutoff. August-born children were generally younger within their grade. The association was not observed in the same way where that cutoff did not apply. This supports concern that relative immaturity can influence identification; it does not prove that every younger child’s diagnosis is mistaken.
Boredom, developmentally excessive demands, and a mismatch between instruction and ability deserve consideration. These possibilities are contextual questions to investigate, rather than established explanations for the national diagnosis rate. Emotional volatility also is not, by itself, a core DSM ADHD criterion.
Other explanations are not merely developmental variation. Sleep disorders, anxiety, depression, learning or language difficulties, and autism can resemble or coexist with ADHD. Hearing and vision problems can make a child appear inattentive. Evaluation must consider alternatives and coexisting conditions rather than assume that one diagnosis excludes another (CDC, 2026c; Wolraich et al., 2019).
Why diagnosis may be more common in American society
Two questions need separating: What contributes to ADHD, and what contributes to receiving an ADHD diagnosis? Genes appear to play a substantial role in ADHD, alongside a complex combination of developmental and environmental influences. There is no single established cause. Prematurity, low birth weight, and certain toxic exposures have been associated with risk, but an association does not necessarily establish an independent cause (NIMH, n.d.; American Psychiatric Association, n.d.).
Recognition and referral are also shaped by the systems surrounding a child. School expectations, available services, family resources, and the quality of assessment can influence which difficulties become visible and how they are interpreted. Academic pressure and limited access to sustained behavioral care are plausible contributors to reliance on diagnosis or medication. They should be presented as possible influences, not a proven explanation for the entire American–international difference.
The question “Why are American parents so quick to call this a mental health issue?” contains an assumption that the available evidence does not establish for parents as a group. Some seek help promptly; some resist diagnosis or medication; others encounter prolonged barriers. Fiks et al. (2013) found that parents’ goals and treatment preferences were associated with different treatment choices. Concern about academic achievement was associated with medication initiation, while behavioral goals were associated with behavioral treatment.
I would therefore ask a more precise question: Under what circumstances do families and schools interpret developmental difficulty as a disorder, and how carefully is that interpretation evaluated? That question permits examination of overidentification without blaming parents who are trying to understand a child’s repeated difficulties. It also permits recognition that a quiet, struggling child may be overlooked.
What medication is expected to do
Amphetamines are one category of stimulant. Methylphenidate is another; it is not an amphetamine. Both affect dopamine and norepinephrine signaling involved in attention and behavioral regulation. Amphetamines increase the release of these neurotransmitters and inhibit their reuptake. Methylphenidate primarily inhibits reuptake. The expected benefit is improved attention, inhibition, and task persistence, with less disruptive activity—not sedation or elimination of childhood energy. The precise therapeutic mechanism is not completely understood (American Academy of Child and Adolescent Psychiatry [AACAP], 2020; Takeda Pharmaceuticals America, Inc., 2026).
Nonstimulants work differently. Atomoxetine inhibits norepinephrine reuptake. Extended-release guanfacine stimulates alpha-2A adrenergic receptors; clonidine is another alpha-2 agonist used for ADHD. These agents can help attention or impulsivity, with effects and tolerability that vary by individual. Nonstimulant options also include viloxazine. “Nonstimulant” does not mean free of adverse effects (AACAP, 2020; Eli Lilly and Company, 2026; Upsher-Smith Laboratories, LLC, 2026).
Effects extend beyond the brain. Stimulants can reduce appetite, disturb sleep, and raise pulse and blood pressure. Guanfacine can cause sleepiness, low blood pressure, and a slower pulse. Atomoxetine can cause gastrointestinal symptoms and affect pulse and blood pressure, and carries a warning about suicidal thinking in children and adolescents. Treatment aims to improve functioning at a tolerable dose; symptoms may lessen substantially without disappearing (Takeda Pharmaceuticals America, Inc., 2026; Eli Lilly and Company, 2026; Upsher-Smith Laboratories, LLC, 2026).
A chronic condition and different medication schedules
A chronic condition does not necessarily require a medicine to remain at a constant concentration around the clock. Stimulants usually provide benefit during a limited period after a dose. Their useful effects generally begin the day they are taken; they do not normally require several weeks of daily accumulation before helping. A dose may be titrated—gradually adjusted—to find an effective and tolerable amount. Titration is not the same as maintaining a constant blood level (AACAP, 2020).
Some children receive a prescriber-planned stimulant break to assess continuing need or address appetite and growth. Other children need daily coverage because difficulties affect family life, activities, relationships, or safety outside school. A break means accepting and evaluating the possibility of symptom return; it does not establish that ADHD was absent. NICE recommends considering planned breaks when growth is significantly affected and periodically reviewing the balance of benefit and harm (National Institute for Health and Care Excellence [NICE], 2018).
Atomoxetine and some other nonstimulants typically require consistent daily use and more time to assess benefit. Guanfacine and clonidine should not be treated as casual, on-and-off medicines: abrupt discontinuation can cause rebound hypertension, and tapering may be necessary. Advice about daily treatment therefore depends on the particular drug and the person’s needs. Medication changes and breaks should be planned with the prescriber (NICE, 2018; Upsher-Smith Laboratories, LLC, 2026).
Harms to the developing brain and body
The possibility of harm deserves careful examination. Appetite suppression, weight loss, and slower growth are established concerns. Insomnia and adverse mood effects can interfere with everyday functioning. Stimulants can rarely produce psychotic symptoms, and cardiac history requires attention. These risks justify monitoring growth, sleep, mood, pulse, and blood pressure (Wolraich et al., 2019).
Long-term cardiovascular uncertainty also matters. A Swedish observational study associated longer cumulative ADHD medication exposure with cardiovascular disease, particularly hypertension and arterial disease (Zhang et al., 2024). The sample included children and adults, and the study cannot prove that medication caused the association. Its findings warrant attention without converting an association into a prediction that a particular child will develop heart disease.
Permanent brain injury is a separate claim. High-dose exposure, misuse, and animal experiments cannot be treated as equivalent to prescribed oral treatment. A review examining developmental dopamine-system effects found reassuring results from nonhuman primate studies designed to approximate clinical exposure (Gerlach et al., 2013). That is not a lifelong guarantee of safety in humans. Current evidence does not establish that appropriately prescribed childhood stimulant treatment inevitably damages the brain. Long-term studies remain limited, and imaging changes alone do not demonstrate injury or protection.
The appropriate comparison includes the effects of inadequately treated ADHD as well as medication risks. A child may also experience educational and relational difficulties from persistent symptoms. The balance is individual and should be reassessed as development and circumstances change (NIMH, n.d.).
Addiction dependence and adulthood
Stimulants have genuine addiction potential. The FDA strengthened class-wide warnings about misuse, abuse, addiction, and overdose in 2023. Risk is especially concerning with excessive doses and unapproved routes such as snorting or injection. Prescribed oral treatment does not make risk disappear, but it is a different exposure from taking a stimulant to become intoxicated (U.S. Food and Drug Administration [FDA], 2023).
Physical dependence means that the body has adapted and withdrawal can follow stopping or reducing a drug. Addiction involves impaired control and continued use despite harm. They are related concepts, but they are not interchangeable. The Adderall XR label warns that physical dependence can occur even with prescribed use. Withdrawal after prolonged exposure may include fatigue, depressed mood, altered sleep, and increased appetite. Returning ADHD symptoms can also occur, and should not automatically be labeled withdrawal or addiction (Takeda Pharmaceuticals America, Inc., 2026).
Molina et al. (2023) followed 579 participants with childhood ADHD into adulthood and found no evidence that more years of stimulant treatment or continuous treatment increased or decreased later substance use or substance use disorder after extensive adjustment for confounding. The follow-up was observational, although it originated in a randomized childhood trial. This finding argues against inevitable adult addiction from childhood treatment. It also does not guarantee that an individual will never misuse medication or develop an addiction.
If pills are replacing skills what is the child learning
This is the question I consider central. A medicine can alter the conditions under which a child attends, pauses, or persists. It cannot supply the experience of resolving disagreement, tolerating disappointment, examining a frightening prediction, organizing responsibilities, or asking for assistance. Those abilities require instruction and practice.
Research illustrates why symptom improvement should not be mistaken for learning. In a randomized crossover study of 173 children, methylphenidate improved classroom behavior and seatwork productivity but did not improve acquisition of the academic material taught during the study (Pelham et al., 2022). This was an academic study, not proof that medication prevents emotional learning. It shows that improved behavior and increased learning are distinct outcomes.
There is no established rule that taking medication causes a child to fail to develop coping skills. Medication may help a child participate in teaching and practice. A child can also know what to do yet have difficulty applying that knowledge consistently. Continued difficulty after stopping medication therefore does not, by itself, demonstrate that skills were never learned. Nevertheless, medication alone cannot be assumed to provide them.
My concern is with a treatment plan that asks only whether the child is quieter or produces more work. I would also want to know what the child is learning: Can the child identify a thought associated with frustration, practice waiting, divide a task into steps, use a reminder, repair a disagreement, and seek support? Progress should be observed in daily situations and supported as the child approaches adulthood. These are proposed educational goals, not promises that coaching will eliminate ADHD.
The American Academy of Pediatrics recommends behavioral parent training and classroom interventions as first-line care for children aged 4 years to the sixth birthday. For school-aged children, it recommends medication together with parent training and/or classroom behavioral intervention, plus educational supports. Adolescent care should include appropriate medication with assent and evidence-based behavioral or training interventions when available (Wolraich et al., 2019).
If medication is later reduced or stopped, planning should include existing routines, accommodations, coaching needs, and a way to assess functioning. Support need not vanish because a prescription ends. The outcome worth pursuing is a person who understands their difficulties, has practiced useful responses, can use available supports, and participates in decisions about treatment. Careful diagnosis, ongoing review of medication, and deliberate teaching all belong in that outcome.
References
American Academy of Child and Adolescent Psychiatry. (2020). Attention-deficit/hyperactivity disorder (ADHD): Parents’ medication guide. https://www.aacap.org/App_Themes/AACAP/docs/resource_centers/resources/med_guides/ADHD_Medication_Guide-web.pdf
American Psychiatric Association. (n.d.). What is ADHD? https://www.psychiatry.org/patients-families/adhd/what-is-adhd
Centers for Disease Control and Prevention. (2026a, July 30). Clinical care of ADHD in children. https://www.cdc.gov/adhd/hcp/clinical-care/index.html
Centers for Disease Control and Prevention. (2026b, July 8). Data on ADHD in children. https://www.cdc.gov/adhd/data/index.html
Centers for Disease Control and Prevention. (2026c, July 30). Diagnosing ADHD. https://www.cdc.gov/adhd/diagnosis/index.html
Eli Lilly and Company. (2026). Strattera (atomoxetine) capsules [Prescribing information]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=309de576-c318-404a-bc15-660c2b1876fb
Fiks, A. G., Mayne, S., DeBartolo, E., Power, T. J., & Guevara, J. P. (2013). Parental preferences and goals regarding ADHD treatment. Pediatrics, 132(4), 692–702. https://doi.org/10.1542/peds.2013-0152
Gerlach, M., Grünblatt, E., & Lange, K. W. (2013). Is the treatment with psychostimulants in children and adolescents with attention deficit hyperactivity disorder harmful for the dopaminergic system? ADHD Attention Deficit and Hyperactivity Disorders, 5(2), 71–81. https://doi.org/10.1007/s12402-013-0105-y
Layton, T. J., Barnett, M. L., Hicks, T. R., & Jena, A. B. (2018). Attention deficit–hyperactivity disorder and month of school enrollment. The New England Journal of Medicine, 379(22), 2122–2130. https://doi.org/10.1056/NEJMoa1806828
Molina, B. S. G., Kennedy, T. M., Howard, A. L., Swanson, J. M., Arnold, L. E., Mitchell, J. T., Stehli, A., Kennedy, E. H., Epstein, J. N., Hechtman, L. T., Hinshaw, S. P., & Vitiello, B. (2023). Association between stimulant treatment and substance use through adolescence into early adulthood. JAMA Psychiatry, 80(9), 933–941. https://doi.org/10.1001/jamapsychiatry.2023.2157
National Institute for Health and Care Excellence. (2018). Attention deficit hyperactivity disorder: Diagnosis and management (NICE Guideline NG87). https://www.nice.org.uk/guidance/ng87
National Institute of Mental Health. (n.d.). Attention-deficit/hyperactivity disorder: What you need to know. https://www.nimh.nih.gov/health/publications/attention-deficit-hyperactivity-disorder-what-you-need-to-know
Pelham, W. E., III, Altszuler, A. R., Merrill, B. M., Raiker, J. S., Macphee, F. L., Ramos, M., Gnagy, E. M., Greiner, A. R., Coles, E. K., Connor, C. M., Lonigan, C. J., Burger, L., Morrow, A. S., Zhao, X., Swanson, J. M., Waxmonsky, J. G., & Pelham, W. E., Jr. (2022). The effect of stimulant medication on the learning of academic curricula in children with ADHD: A randomized crossover study. Journal of Consulting and Clinical Psychology, 90(5), 367–380. https://doi.org/10.1037/ccp0000725
Polanczyk, G. V., Willcutt, E. G., Salum, G. A., Kieling, C., & Rohde, L. A. (2014). ADHD prevalence estimates across three decades: An updated systematic review and meta-regression analysis. International Journal of Epidemiology, 43(2), 434–442. https://doi.org/10.1093/ije/dyt261
Salari, N., Ghasemi, H., Abdoli, N., Rahmani, A., Shiri, M. H., Hashemian, A. H., Akbari, H., & Mohammadi, M. (2023). The global prevalence of ADHD in children and adolescents: A systematic review and meta-analysis. Italian Journal of Pediatrics, 49, Article 48. https://doi.org/10.1186/s13052-023-01456-1
Takeda Pharmaceuticals America, Inc. (2026). Adderall XR (mixed salts of a single-entity amphetamine product) extended-release capsules [Prescribing information]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aff45863-ffe1-4d4f-8acf-c7081512a6c0
Upsher-Smith Laboratories, LLC. (2026). Guanfacine extended-release tablets [Prescribing information]. DailyMed. https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=07a701e2-39b7-4bb1-a7c7-d9baed4ab18a
U.S. Food and Drug Administration. (2023, May 11). FDA updating warnings to improve safe use of prescription stimulants used to treat ADHD and other conditions. https://www.fda.gov/drugs/drug-safety-communications/fda-updating-warnings-improve-safe-use-prescription-stimulants-used-treat-adhd-and-other-conditions
Wolraich, M. L., Hagan, J. F., Jr., Allan, C., Chan, E., Davison, D., Earls, M., Evans, S. W., Flinn, S. K., Froehlich, T., Frost, J., Holbrook, J. R., Lehmann, C. U., Lessin, H. R., Okechukwu, K., Pierce, K. L., Winner, J. D., & Zurhellen, W. (2019). Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics, 144(4), Article e20192528. https://doi.org/10.1542/peds.2019-2528
Zhang, L., Li, L., Andell, P., Garcia-Argibay, M., Quinn, P. D., D’Onofrio, B. M., Brikell, I., Kuja-Halkola, R., Lichtenstein, P., Johnell, K., Larsson, H., & Chang, Z. (2024). Attention-deficit/hyperactivity disorder medications and long-term risk of cardiovascular diseases. JAMA Psychiatry, 81(2), 178–187. https://doi.org/10.1001/jamapsychiatry.2023.4294